NCT07895420 Comparing Intravitreal Injection Pain Scores Using Iheezo (Chloroprocaine Hcl Ophthalmic Gel 3%) Versus Subconjunctival Lidocaine (2%): A Randomized, Controlled Trial
| NCT ID | NCT07895420 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Retina Research Institute, LLC |
| Condition | No Condition |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2025-10-30 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 80 participants in total. It began in 2025-10-30 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This will be a prospective, randomized, controlled non-inferiority trial comparing the efficacy of Iheezo versus subconjunctival 2% lidocaine in reducing intravitreal injection pain scores up to 24 hours after injection.
Eligibility Criteria
Inclusion Criteria: * At least 1 previous intravitreal injection in the last 180 days from screening. Exclusion Criteria: * History of more than 13 intravitreal injections.
Contact & Investigator
Nicholas Iafe, MD
PRINCIPAL INVESTIGATOR
The Retina Institute
Frequently Asked Questions
Who can join the NCT07895420 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying No Condition. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07895420 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07895420 currently recruiting?
Yes, NCT07895420 is actively recruiting participants. Contact the research team at allan.braverman@rc-stl.com for enrollment information.
Where is the NCT07895420 trial being conducted?
This trial is being conducted at Glen Carbon, United States, Chesterfield, United States, City of Saint Peters, United States, St Louis, United States.
Who is sponsoring the NCT07895420 clinical trial?
NCT07895420 is sponsored by Retina Research Institute, LLC. The principal investigator is Nicholas Iafe, MD at The Retina Institute. The trial plans to enroll 80 participants.